OBJECTIVE: To determine if ventricular cerebrospinal fluid (vCSF) alpha-tocopherol levels in Parkinson's disease (PD) patients can be increased by oral alpha-tocopherol supplementation and whether vCSF levels are linearly related to plasma alpha-tocopherol levels. BACKGROUND: In spite of its putative neuroprotective properties, alpha-tocopherol has failed to alter PD clinical progression. However, the ability of supplemental alpha-tocopherol to affect brain or vCSF levels has never been assessed in humans nor has a dose response curve for alpha-tocopherol in vCSF been established. METHODS: Five PD patients with Ommaya catheters received oral dl-alpha-tocopherol over 5 months. Each patient ingested alpha-tocopherol daily with monthly dosage increases (400, 800, 1,600, 3,200, 4,000 IU/day). Plasma and vCSF samples were obtained at baseline and at the end of each month. Alpha-tocopherol levels were determined in triplicate by high-pressure liquid chromatography with fluorometric and electrochemical detection. RESULTS: At baseline, endogenous alpha-tocopherol was detected in plasma and vCSF, with a greater than one-hundred-fold difference between the fluid compartments (mean plasma level 18.76 microM/l (SD +/- 4.69) versus mean CSF level 0.114 microM/l (SD +/- 0.084). A clear dose-response curve occurred in plasma, with statistically significant increases over baseline developing even with 400 IU/d. With higher doses, a significant increase continued without evidence of saturation. However, there was no significant increase in vCSF alpha-tocopherol levels at any dose, including the supraclinical (4,000 IU/d). There was no correlation between plasma and vCSF alpha-tocopherol levels. CONCLUSION: Oral alpha-tocopherol supplementation, even at supraclinical doses, fails to increase vCSF alpha-tocopherol levels. This lack of change may be due to limited passage across the blood-brain barrier or very rapid alpha-tocopherol metabolism. All prior negative studies on efficacy of alpha-tocopherol in PD may need reevaluation in light of these pharmacologic data.
OBJECTIVE: To determine if ventricular cerebrospinal fluid (vCSF) alpha-tocopherol levels in Parkinson's disease (PD) patients can be increased by oral alpha-tocopherol supplementation and whether vCSF levels are linearly related to plasma alpha-tocopherol levels. BACKGROUND: In spite of its putative neuroprotective properties, alpha-tocopherol has failed to alter PD clinical progression. However, the ability of supplemental alpha-tocopherol to affect brain or vCSF levels has never been assessed in humans nor has a dose response curve for alpha-tocopherol in vCSF been established. METHODS: Five PDpatients with Ommaya catheters received oral dl-alpha-tocopherol over 5 months. Each patient ingested alpha-tocopherol daily with monthly dosage increases (400, 800, 1,600, 3,200, 4,000 IU/day). Plasma and vCSF samples were obtained at baseline and at the end of each month. Alpha-tocopherol levels were determined in triplicate by high-pressure liquid chromatography with fluorometric and electrochemical detection. RESULTS: At baseline, endogenous alpha-tocopherol was detected in plasma and vCSF, with a greater than one-hundred-fold difference between the fluid compartments (mean plasma level 18.76 microM/l (SD +/- 4.69) versus mean CSF level 0.114 microM/l (SD +/- 0.084). A clear dose-response curve occurred in plasma, with statistically significant increases over baseline developing even with 400 IU/d. With higher doses, a significant increase continued without evidence of saturation. However, there was no significant increase in vCSF alpha-tocopherol levels at any dose, including the supraclinical (4,000 IU/d). There was no correlation between plasma and vCSF alpha-tocopherol levels. CONCLUSION: Oral alpha-tocopherol supplementation, even at supraclinical doses, fails to increase vCSF alpha-tocopherol levels. This lack of change may be due to limited passage across the blood-brain barrier or very rapid alpha-tocopherol metabolism. All prior negative studies on efficacy of alpha-tocopherol in PD may need reevaluation in light of these pharmacologic data.
Authors: Matthew J Haney; Natalia L Klyachko; Yuling Zhao; Richa Gupta; Evgeniya G Plotnikova; Zhijian He; Tejash Patel; Aleksandr Piroyan; Marina Sokolsky; Alexander V Kabanov; Elena V Batrakova Journal: J Control Release Date: 2015-03-31 Impact factor: 9.776
Authors: Ingrid Kratzer; Eva Bernhart; Andrea Wintersperger; Astrid Hammer; Sabine Waltl; Ernst Malle; Günther Sperk; Georg Wietzorrek; Hans Dieplinger; Wolfgang Sattler Journal: J Neurochem Date: 2008-11-27 Impact factor: 5.372
Authors: Ira T Lott; Eric Doran; Vinh Q Nguyen; Anne Tournay; Elizabeth Head; Daniel L Gillen Journal: Am J Med Genet A Date: 2011-07-07 Impact factor: 2.802
Authors: C Mühlhausen; G F Hoffmann; K A Strauss; S Kölker; J G Okun; C R Greenberg; E R Naughten; K Ullrich Journal: J Inherit Metab Dis Date: 2004 Impact factor: 4.982
Authors: Matthew J Haney; Poornima Suresh; Yuling Zhao; Georgette D Kanmogne; Irena Kadiu; Marina Sokolsky-Papkov; Natalia L Klyachko; R Lee Mosley; Alexander V Kabanov; Howard E Gendelman; Elena V Batrakova Journal: Nanomedicine (Lond) Date: 2012-01-11 Impact factor: 5.307
Authors: F J Jiménez-Jiménez; F de Bustos; J A Molina; J Benito-León; A Tallón-Barranco; T Gasalla; M Ortí-Pareja; F Guillamón; J C Rubio; J Arenas; R Enríquez-de-Salamanca Journal: J Neural Transm (Vienna) Date: 1997 Impact factor: 3.575
Authors: Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman Journal: Bioconjug Chem Date: 2007-08-31 Impact factor: 4.774
Authors: Siân C Barber; Adrian Higginbottom; Richard J Mead; Stuart Barber; Pamela J Shaw Journal: Free Radic Biol Med Date: 2009-01-30 Impact factor: 7.376